CAS
REGN icon

CTC Alternative Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

CTC Alternative Strategies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-546
Closed -$307K – 86
2025
Q3 		$307K Buy
+546
New +$309K 0.49% 56
2023
Q4 		– Sell
-600
Closed -$494K – 121
2023
Q3 		$494K Buy
+600
New +$472K 0.93% 33
2013
Q3 		– Sell
-2,700
Closed -$607K – 175
2013
Q2 		$607K Buy
+2,700
New +$629K 0.16% 46

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

CTC Alternative Strategies's REGN Position: Q4 2025 in Review

CTC Alternative Strategies sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 546 shares — an estimated $307K sold.

CTC Alternative Strategies first reported a position in REGN in Q2 2013 and held it in 3 quarters. The position peaked at $607K in Q2 2013. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • CTC Alternative Strategies reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • CTC Alternative Strategies sold 546 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $307K.
  • CTC Alternative Strategies first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • CTC Alternative Strategies's Regeneron Pharmaceuticals position peaked at $607K in Q2 2013.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on CTC Alternative Strategies's 13F filing for Q4 2025, filed 18 Feb 2026.